Dr. Reddy’s Laboratories Limited (NYSE:RDY) Stock Holdings Increased by Sivia Capital Partners LLC

Sivia Capital Partners LLC raised its holdings in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 394.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 30,498 shares of the company’s stock after buying an additional 24,336 shares during the period. Sivia Capital Partners LLC’s holdings in Dr. Reddy’s Laboratories were worth $482,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. World Investment Advisors LLC purchased a new stake in shares of Dr. Reddy’s Laboratories during the third quarter valued at $3,459,000. Nordea Investment Management AB raised its holdings in Dr. Reddy’s Laboratories by 441.8% during the 4th quarter. Nordea Investment Management AB now owns 125,363 shares of the company’s stock worth $1,992,000 after buying an additional 102,226 shares during the period. Frank Rimerman Advisors LLC purchased a new stake in Dr. Reddy’s Laboratories during the second quarter valued at about $2,633,000. GAMMA Investing LLC boosted its holdings in shares of Dr. Reddy’s Laboratories by 369.9% in the fourth quarter. GAMMA Investing LLC now owns 6,799 shares of the company’s stock worth $107,000 after buying an additional 5,352 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Dr. Reddy’s Laboratories by 109.3% in the third quarter. Geode Capital Management LLC now owns 13,254 shares of the company’s stock worth $1,053,000 after acquiring an additional 6,920 shares in the last quarter. Institutional investors own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Stock Down 0.7 %

Shares of NYSE RDY traded down $0.11 during trading hours on Monday, hitting $15.31. The stock had a trading volume of 1,039,240 shares, compared to its average volume of 1,953,938. The firm’s 50-day moving average price is $14.84 and its two-hundred day moving average price is $15.55. Dr. Reddy’s Laboratories Limited has a 52 week low of $13.43 and a 52 week high of $16.89. The company has a market capitalization of $12.78 billion, a P/E ratio of 24.46 and a beta of 0.53. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.36 and a current ratio of 1.92.

Wall Street Analyst Weigh In

A number of research firms recently commented on RDY. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Nomura downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th. Finally, Barclays decreased their target price on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.